| Budget Amount *help |
¥41,470,000 (Direct Cost: ¥31,900,000、Indirect Cost: ¥9,570,000)
Fiscal Year 2017: ¥8,710,000 (Direct Cost: ¥6,700,000、Indirect Cost: ¥2,010,000)
Fiscal Year 2016: ¥16,770,000 (Direct Cost: ¥12,900,000、Indirect Cost: ¥3,870,000)
Fiscal Year 2015: ¥15,990,000 (Direct Cost: ¥12,300,000、Indirect Cost: ¥3,690,000)
|
|---|
| Outline of Final Research Achievements |
Pulmonary arterial hypertension (PAH) is characterized by histological changes in the distal pulmonary arteries. In addition to genetic considerations, many environmental factors are involved in the development of PAH. All of these factors constitute complex interactions that affect pulmonary vasculature in a multi-stage manner. Thus, the identification of genes, which cause the abnormal characteristics of PASMCs, should be useful for the development of novel therapies for PAH. The characteristics of PASMCs of PAH patients (PAH-PASMCs) are different from those of healthy controls, in terms of pro-proliferative and anti-apoptotic features, which are similar to those of cancer cells. These features of PAH-PASMCs may be caused by some unknown pathogenic genes that promote PAH. Since conventional pulmonary vasodilators have limited efficacy for the treatment of severe PAH, we have performed a series of screens and found novel therapeutic targets.
|
